Literature DB >> 15167683

Tezosentan counteracts endotoxin-induced pulmonary edema and improves gas exchange.

Patrik Rossi1, Michael Wanecek, David Konrad, Anders Oldner.   

Abstract

Sepsis-induced acute lung injury is still associated with high morbidity and mortality. The pathophysiology is complex, and markers of injury include increased extravascular lung water. To evaluate the effects of the novel dual endothelin receptor antagonist tezosentan on endotoxin-induced changes in extravascular lung water and gas exchange, 16 pigs were anaesthetized and catheterized. Twelve animals were subjected to 5 h of endotoxemia. After 2 h, six of these animals received a bolus of tezosentan 1 mg kg(-1) followed by a continuous infusion of 1 mg kg(-1) h(-1) to the end of the experiment at 5 h. Conventional pulmonary and hemodynamic parameters were measured. Extravascular lung water was determined in these pigs after 5 h of endotoxemia, as well as in the four additional nonendotoxemic sham animals. Tezosentan in the current dosage counteracted the deterioration of lung function caused by endotoxin, as measured by dead space, venous admixture, and compliance. In addition, pulmonary hypertension was attenuated. Tezosentan had a marked effect on the endotoxin-induced increase in extravascular lung water that was reduced to levels observed in nonendotoxemic sham animals. These results suggest that endothelin is involved in endotoxin-induced lung injury and the development of pulmonary edema. Dual endothelin receptor antagonism may be of value in the treatment of sepsis-related acute lung injury.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167683     DOI: 10.1097/01.shk.0000126147.76311.18

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

1.  Endotoxemic pulmonary hypertension is largely mediated by endothelin-induced venous constriction.

Authors:  Patrik Rossi; Björn Persson; Piet J M Boels; Anders Arner; Eddie Weitzberg; Anders Oldner
Journal:  Intensive Care Med       Date:  2008-01-24       Impact factor: 17.440

2.  Tezosentan-induced attenuation of lung injury in endotoxemic sheep is associated with reduced activation of protein kinase C.

Authors:  Vladimir Kuklin; Mikhail Kirov; Mikhail Sovershaev; Thomas Andreasen; Ole C Ingebretsen; Kirsti Ytrehus; Lars Bjertnaes
Journal:  Crit Care       Date:  2005-03-14       Impact factor: 9.097

3.  The role of endothelin-1 in hyperoxia-induced lung injury in mice.

Authors:  Walid Habre; Ferenc Peták; Isabelle Ruchonnet-Metrailler; Yves Donati; Jean-Francois Tolsa; Eniko Lele; Gergely Albu; Morice Beghetti; Constance Barazzone-Argiroffo
Journal:  Respir Res       Date:  2006-03-27

4.  Endothelial Expression of Endothelin Receptor A in the Systemic Capillary Leak Syndrome.

Authors:  Albert C Sek; Zhihui Xie; Kaoru Terai; Lauren M Long; Celeste Nelson; Arkadiusz Z Dudek; Kirk M Druey
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

5.  Preferential recruitment of neutrophils by endothelin-1 in acute lung inflammation induced by lipopolysaccharide or cigarette smoke.

Authors:  Tapan Bhavsar; Xing Jian Liu; Hardik Patel; Ralph Stephani; Jerome O Cantor
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

6.  Endothelin receptor antagonist improves donor lung function in an ex vivo perfusion system.

Authors:  K Walweel; K Skeggs; A C Boon; L E See Hoe; M Bouquet; N G Obonyo; S E Pedersen; S D Diab; M R Passmore; K Hyslop; E S Wood; J Reid; S M Colombo; N J Bartnikowski; M A Wells; D Black; L P Pimenta; A K Stevenson; K Bisht; L Marshall; D A Prabhu; L James; D G Platts; P S Macdonald; D C McGiffin; J Y Suen; J F Fraser
Journal:  J Biomed Sci       Date:  2020-10-02       Impact factor: 8.410

Review 7.  Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.

Authors:  Yujiro Matsuishi; Bryan J Mathis; Nobutake Shimojo; Jesmin Subrina; Nobuko Okubo; Yoshiaki Inoue
Journal:  Biomedicines       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.